Page last updated: 2024-11-06

biotinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Biotinamide is a synthetic derivative of biotin, a vital B vitamin. It is produced by chemical modification of biotin, typically through the reaction of biotin with ammonia. Research into biotinamide explores its potential as a therapeutic agent in various conditions. It has been investigated for its potential effects on hair growth, skin health, and the treatment of biotin deficiency. Studies suggest that biotinamide may be more bioavailable than biotin, potentially leading to greater therapeutic efficacy. However, further research is needed to fully understand its effects and safety profile. Biotinamide's potential as a prodrug for biotin is also being explored, with research focusing on its ability to release biotin at specific target sites in the body. The study of biotinamide is driven by the desire to develop novel treatments for biotin-related disorders and to improve the delivery and efficacy of biotin.'

biotin amide : A monocarboxylic acid amide derived from biotin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID83831
CHEBI ID16615
SCHEMBL ID597444
MeSH IDM0245541

Synonyms (14)

Synonym
5-[(3as,4s,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanamide
CHEBI:16615
biotinamide
C01893
biotin amide
6929-42-6
1h-thieno(3,4-d)imidazole-4-valeramide, hexahydro-2-oxo-, (+)-
1h-thieno(3,4-d)imidazole-4-pentanamide, hexahydro-2-oxo-, (3as,4s,6ar)-
(+)-hexahydro-2-oxo-1h-thieno(3,4-d)imidazole-4-valeramide
SCHEMBL597444
DTXSID70219349
Q27101999
5-((3as,4s,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl)pentanamide
Z194976344

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
biotinsCompounds containing a biotin (5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid) skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Biotin metabolism, including IMDs912

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (23.81)18.2507
2000's11 (52.38)29.6817
2010's5 (23.81)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.07 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]